- Israel has entered into an agreement with Novavax(NASDAQ:NVAX)to buy 5 million doses of the company’s COVID-19 vaccine, the country’s health ministry said Friday, according to Reuters.The financial terms of the deal which also includes an option for another 5 million doses were not disclosed.
- The first batches of the vaccine will arrive in the coming months subject to regulatory clearance, giving an alternative to a country where the immunization drive for COVID-19 was mainly led by messenger RNA-based vaccine from Pfizer(NYSE:PFE)and BioNTech(NASDAQ:BNTX).
- Multiple regulators, including the European Union (EU) and the World Health Organization (WHO), have cleared Novavax’s (NVAX) protein-based COVID-19 vaccine, named NVX-CoV2373.
- In December, the company announced the submission of a data package to the FDA seeking regulatory clearance for the shot in the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments